



NDA 21266/S035
NDA 21267/S040
NDA 21630/S026

SUPPLEMENT APPROVAL

C.P. Pharmaceuticals International C.V.
c/o Pfizer, Inc.
Attention: Anthony Helstosky
Director, Worldwide Regulatory Strategy
235 East 42nd Street
New York, NY 10017

Dear Mr. Helstosky:

Please refer to your Supplemental New Drug Applications (sNDAs) dated October 28, 2011, received October 28, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for:

NDA 21266/S035	VFEND (voriconazole) Tablets
NDA 21267/S040	VFEND I.V. (voriconazole) for Infusion
NDA 21630/S026	VFEND (voriconazole) for Oral Suspension

These “Prior Approval” supplemental new drug applications provide for information on fluorosis and periostitis reported with postmarketing use of VFEND in the **HIGHLIGHTS, WARNINGS AND PRECAUTIONS** section and **ADVERSE REACTIONS** section, **Postmarketing Experience** subsection.

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(1)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at (301) 796-0797.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Deputy Director for Safety
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
11/16/2011